10-Q: Acurx Pharmaceuticals Narrows Losses, Boosts Cash

Acurx Pharmaceuticals reported significantly reduced net losses and increased cash reserves for the nine months ended September 30, 2025, while regaining Nasdaq compliance.

Summary

• Net loss for the nine months ended September 30, 2025, decreased by 44% to $6.4 million, compared to $11.3 million for the same period in 2024.
• Research and Development expenses decreased by 66% to $1.6 million for the nine months ended September 30, 2025, down from $4.6 million in 2024.
• General and Administrative expenses decreased by 27% to $4.9 million for the nine months ended September 30, 2025, compared to $6.8 million in 2024.
• Cash balance increased to $5.9 million as of September 30, 2025, from $3.7 million at December 31, 2024.
• The company regained compliance with Nasdaq's minimum bid price and stockholders' equity requirements on August 26, 2025.
• Stockholders approved an increase in authorized common stock from 200,000,000 to 250,000,000 shares on September 16, 2025.
• A 1-for-20 reverse stock split was effected on August 4, 2025.
• The company continues to face substantial doubt about its ability to continue as a going concern, requiring additional funding to sustain operations.

Sentiment

Score: 6

Explanation: While the company significantly reduced losses, increased cash, and regained Nasdaq compliance, the explicit 'going concern' warning and continued reliance on external funding for the foreseeable future temper the overall positive financial improvements. The progress in clinical trials and strategic partnerships are positive but still future-dependent.

Positives

• Net loss significantly decreased by $4.9 million (44%) for the nine months ended September 30, 2025, compared to the prior year.
• Operating expenses decreased substantially, with R&D down 66% and G&A down 27% for the nine-month period.
• Cash balance increased to $5.9 million, providing improved liquidity compared to the end of 2024.
• Regained full compliance with Nasdaq's minimum bid price and stockholders' equity listing requirements.
• Successful capital raises through registered direct offerings, warrant exercises, and an equity line of credit provided $7.8 million in net cash from financing activities for the nine months ended September 30, 2025.

Negatives

• The company has incurred significant net losses since inception, totaling approximately $73.7 million as of September 30, 2025.
• Management expressed substantial doubt about the company's ability to continue as a going concern, indicating a need for additional resources within the next 12 months.
• The company has not generated any revenue since inception and does not expect to in the near future.
• Cash balance of $5.9 million is not sufficient to meet anticipated cash requirements for at least 12 months from the issuance of the financial statements.

Risks

• The company is a clinical-stage company with a limited operating history, making future performance difficult to predict.
• Significant net losses are anticipated to continue, and profitability may never be achieved or maintained.
• Substantial additional funding is required, and inability to raise capital could force delays or elimination of product development or commercialization efforts.
• Raising additional capital may dilute existing stockholders, restrict operations, or require relinquishing rights to technologies or product candidates.
• Reliance on the success of lead product candidate, ibezapolstat, for CDI treatment; failure to commercialize or significant delays would materially harm the business.
• Serious adverse or inappropriate side effects identified during development could lead to abandonment or limitation of product candidate development.
• Ibezapolstat or other product candidates may not achieve sufficient market acceptance even if regulatory approval is obtained.
• Exposure to product liability and non-clinical/clinical liability risks could place a substantial financial burden.
• Operations substantially depend on the management team and ability to hire key personnel; loss of any could disrupt business.
• Failure to complete or meet key milestones for technology and proposed products would significantly impair financial condition.
• Competition from larger, better-capitalized companies and development of competing products could outperform or supplant proposed products.
• A pandemic, epidemic, or infectious disease outbreak (e.g., COVID-19) could materially and adversely affect the business.
• Global market and economic conditions, including inflation, interest rates, and geopolitical conflicts (Russia-Ukraine, Israel-Hamas), may negatively impact business, financial condition, and share price.
• Results of preclinical studies and early clinical trials are not necessarily predictive of future results; interim data may change.
• Clinical trials of lead product candidate may fail to demonstrate safety and efficacy, leading to additional costs or delays.
• Unforeseen events in clinical trials could delay or prevent marketing approval or commercialization.
• Inability to obtain regulatory approval in the U.S. or foreign jurisdictions would impair revenue generation.
• Risks associated with operating in foreign countries could adversely affect product development if extended outside the U.S.
• Results of operations may be adversely affected by current and potential future healthcare legislative and regulatory actions.
• Inability to establish sales and marketing capabilities or enter third-party agreements could hinder commercialization success.
• Reliance on third parties for manufacturing product candidates increases risk of insufficient quantities or unacceptable costs.
• Inability of ultimate users to obtain adequate reimbursement from third-party payers could limit market acceptance and revenue.
• Involvement in lawsuits to protect or enforce patents could be expensive and time-consuming.
• Intellectual property litigation could cause substantial resource expenditure and distract personnel.
• Need to license certain intellectual property from third parties, which may not be available or on commercially reasonable terms.
• Inability to adequately protect or enforce intellectual property rights could lead to loss of valuable rights or costly litigation.
• Failure to protect the confidentiality of trade secrets would harm business and competitive position.
• The price of common stock may be volatile, leading to potential loss of investment.
• Nasdaq may delist securities, limiting investor ability to transact and subjecting the company to additional trading restrictions.
• Largest stockholders exercise significant influence over the company.
• Cyber incidents or attacks could result in information theft, data corruption, operational disruption, and/or financial loss.
• Failure to comply with evolving privacy and data protection laws could adversely affect business.
• Limitations on the effectiveness of internal controls could lead to error or fraud.
• Estimates and judgments in financial statements could prove inaccurate.
• Failure to comply with the United States Foreign Corrupt Practices Act could subject the company to penalties.
• Litigation may adversely affect business, financial condition, and results of operations.
• Failure to comply with environmental, health, and safety laws and regulations could lead to fines or penalties.
• If securities or industry analysts do not publish research or publish negative reports, share price and trading volume could decline.
• Delaware law contains anti-takeover provisions that could deter beneficial takeover attempts.
• Exclusive forum provisions in corporate charter documents could limit stockholders' ability to obtain a favorable judicial forum.

Future Outlook

Management expects to continue incurring losses for the foreseeable future and will require additional resources to sustain operations until profitability is achieved. The company plans to seek additional equity financing and grant funding. It also expects to partner with a fully-integrated pharmaceutical company for late-stage clinical trials and commercialization of ibezapolstat or conduct Phase 3 clinical trials prior to such a partnership, continuously reviewing opportunities up to FDA approval.

Management Comments

• Management believes that the Company will continue to incur losses for the foreseeable future and will need additional resources to sustain its operations until it can achieve profitability and positive cash flows, if ever.
• Management plans to seek additional equity financing and grant funding, but cannot assure that such financing and funding will be available at acceptable terms, or at all.
• We expect to partner with a fully-integrated pharmaceutical company for late-stage clinical trials and commercialization or conduct Phase 3 clinical trials prior to such partnership and continue to review partnership opportunities on an ongoing basis up to FDA approval.

Industry Context

Acurx Pharmaceuticals operates in the biopharmaceutical industry, specifically targeting the global public health threat of Antimicrobial Resistance (AMR) as identified by the WHO, CDC, and FDA. The company is developing a novel class of antibiotics, DNA pol IIIC inhibitors, for difficult-to-treat Gram-positive bacterial infections like Clostridioides difficile (CDI), MRSA, VRE, and PRSP. The company believes its lead candidate, ibezapolstat, is the first DNA pol IIIC inhibitor to enter Phase 3 clinical trials, positioning it uniquely in a market with an inadequate research and development pipeline for new antibiotics.

Corporate Governance

Legal Proceedings

• Not currently a party to any litigation or legal proceedings that are likely to have a material adverse effect on the business.

Related Party Transactions

• Affiliate Investors participated in the January 2025 Registered Direct Offering, purchasing 8,374 shares of common stock and Series E Warrants.
• Affiliate Investors exercised 2,961 Series B Warrants in January 2024, generating approximately $0.2 million in proceeds for the company.

Stakeholder Impact

• Shareholders experienced dilution from multiple equity financings and warrant exercises, but also benefited from the company regaining Nasdaq compliance.
• Employees and consultants received share-based compensation, aligning their interests with company performance.
• Creditors and investors face ongoing risk due to the company's 'going concern' status and reliance on future capital raises.

Next Steps

• Seek additional equity financing and grant funding to sustain operations.
• Continue research and development activities for product candidates.
• Initiate additional clinical trials for product candidates.
• Seek regulatory approval for product candidates.
• Evaluate and pursue strategic partnerships for late-stage clinical trials and commercialization of ibezapolstat.
• Monitor and potentially address any future Nasdaq listing requirements.

Key Dates

Recommendation

Acurx Pharmaceuticals has demonstrated improved financial performance by significantly reducing net losses and operating expenses, while also successfully raising capital and regaining Nasdaq compliance. These are positive indicators of operational efficiency and market viability. However, the explicit 'going concern' warning, the continued absence of revenue, and the ongoing need for substantial future funding introduce significant uncertainty and risk. While the company's lead product candidate, ibezapolstat, shows promise in a critical area (AMR), its commercial success is still years away and dependent on further clinical trials and regulatory approvals. Therefore, a 'hold' recommendation is appropriate for seasoned investors, acknowledging the positive operational improvements and potential upside, but also recognizing the substantial inherent risks and the need for further clarity on long-term funding and product commercialization.

Keywords

Biopharmaceutical, Antibiotics, C. difficile, CDI, MRSA, VRE, DNA polymerase IIIC inhibitor, Ibezapolstat, Clinical stage, Drug development, SEC filing, Nasdaq compliance, Capital raise, Going concern, Pharmaceuticals, Biotech, Antimicrobial Resistance, AMR